摘要
目的探讨丹参酮ⅡA磺酸钠对慢性阻塞性肺疾病(COPD)气道重塑大鼠过氧化物酶体增殖物活化受体γ(PPARγ)、核因子-κB的影响。方法通过气管内注射脂多糖及吸烟建立COPD气道重塑大鼠模型。健康Wistar大鼠40只,随机分为四组:正常组(n=10)、模型组(n=10)、丹参酮ⅡA磺酸钠治疗组(n=10)、地塞米松治疗组(n=10),应用酶联免疫吸附(ELISA)法检测金属基质蛋白酶-2(MMP-2)、金属基质蛋白酶-9(MMP-9)、金属基质蛋白酶抑制物-1(TIMP-1)、金属基质蛋白酶抑制物-2(TIMP-2)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)的含量,以逆转录聚合酶链反应(RT-PCR)法以及蛋白免疫印记法(Western-blot法)检测PPARγ、NF-κB mRNA及蛋白质表达水平。结果与正常组比较,模型组血清MMP-2、MMP-9、TNF-α、IL-6的含量明显升高,TIMP-1、TIMP-2则明显降低,而且模型组气管组织PPARγmRNA和蛋白质表达水平明显降低,NF-κB mRNA和蛋白质表达水平则明显升高,差异有显著性(均P<0.05),经予丹参酮ⅡA磺酸钠治疗后,血清MMP-2、MMP-9、TNF-α、IL-6的含量明显降低,TIMP-1、TIMP-2则明显升高,且模型组气管组织PPARγmRNA和蛋白质表达水平明显升高,NF-κB mRNA和蛋白质表达水平则明显降低,丹参酮ⅡA磺酸钠治疗组与正常组及地塞米松组比较差异无显著性(均P>0.05)。结论丹参酮ⅡA磺酸钠通过调节PPARγ、NF-κB mRNA及蛋白质的表达水平,抑制气道重塑因子MMP-2、MMP-9、TIMP-1、TIMP-2、TNF-α、IL-6水平,防止气道重塑。
Objective To investigate the influence of TanshioneⅡA on PPARγand NF-κB in the airway remodeling of rat with COPD.Methods The model of airway remodeling of rat with COPD was established by intratracheal injection of lipopolysaccharide combined with cigarette smoking.40 healthy Wistar rats were randomly separated into 4groups which were normal control group,model control group,TanshioneⅡA treatment group and dexamethasone treatment group（10rats in each group）.Levels of MMP-2,MMP-9,TIMP-1,TIMP-2,TNF-αand IL-6were measured by ELISA,mRNA and protein levels of PPARγand NF-κB were evaluated with RT-PCR and western-blot（WB）respectively.Results In model control group,levels of MMP-2,MMP-9,TNF-αand IL-6were significantly higher,also mRNA and protein levels of NF-κB up-regulated,but levels of TIMP-1,TIMP-2and mRNA and protein levels of PPARγwere significantly lower than those in normal control group,and there were no statistical significantly differences（all P〈0.05）.But these change could be attenuated by Tanshione Ⅱ A treatment group,compared with normal control group and dexamethasone treatment group,there were no statistical significantly differences in TanshioneⅡA treatment group（all P〈0.05）.Conclusion TanshioneⅡA may reverse the airway remodeling through PPARγand NF-κB regulating MMP-2,MMP-9,TIMP-1,TIMP-2,TNF-αand IL-6.
出处
《贵州医药》
CAS
2016年第5期466-468,共3页
Guizhou Medical Journal
基金
贵州省中医药管理局
民族医药科学技术研究课题(编号:QZYY2013-84)
